R&D Views & Analysis | pharmaphorum

Views & Analysis

Weekly roundup: More questions for Novartis in Zolgensma sca...

It’s been a tough month for Novartis, with the company facing a deepening scandal over data manipulation for its spinal muscular atrophy (SMA) gene therapy Zolgensma.

Views & Analysis

Translating microbiome research into treatments

The human microbiome is a powerful and dynamic ecosystem of microbes that live on and within our bodies.

Views & Analysis

Sharing success to unlock the “triple win” of joint working

The fortunes of the NHS and the UK’s life sciences industry are intertwined, with each sector’s success or failure heavily dependent on the other.

Views & Analysis

Bringing innovative trials to the UK

We spoke with the National Institute for Health Research’s (NIHR) senior business development manager, Anjna Rising, to learn how the NIHR is approaching innovative clinical trials and fosterin

Views & Analysis

Tackling the remaining challenges of multiple sclerosis

With Merck KGaA’s multiple sclerosis drug evobrutinib entering phase 3 trials, we spoke to the company’s Fernando Dangond and MS expert Dr Xavier Montalban to get their views on the biggest

Views & Analysis